Cardiovascular / Cardiology
BioVentrix® Closes $48.5 Million Series A Financing
BioVentrix, Inc., a privately held medical device company developing minimally invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process in patients with congestive heart failure, today announced the completion of $48.5 million Series A round...